{"disease":{"id":"platinum-resistant-epithelial-ovarian-cancer","name":"platinum resistant epithelial ovarian cancer"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04244552","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Atreca, Inc.","has_results":false},{"nct_id":"NCT05483933","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT03311334","title":"A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":true},{"nct_id":"NCT07117877","title":"Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05243524","title":"Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","has_results":false},{"nct_id":"NCT03081702","title":"A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06545617","title":"A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}